贝伐珠单抗联合腹腔热灌注化疗治疗结直肠癌并发恶性腹水的临床分析  

Bevacizumab combined with hyperthermic intraperitoneal chemotherapy in the treatment of colorectal cancer with malignant ascites

作　　者：王霞 王会志[2] 姜润学[2] WANG Xia;WANG Hui-zhi;JIANG Run-xue(Department of Oncology,Tangshan Hongci Hospital,Tangshan 063000,China;Department of Oncology,Tangshan People’s Hospital,Tangshan 063000,China)

机构地区：[1]唐山弘慈医院肿瘤科,河北唐山063000 [2]唐山市人民医院肿瘤科,河北唐山063000

出　　处：《实用药物与临床》2020年第10期905-908,共4页Practical Pharmacy and Clinical Remedies

基　　金：河北省科技计划项目(182777136)。

摘　　要：目的评价结直肠癌并发恶性腹水患者行贝伐珠单抗(Bevacizumab)联合腹腔热灌注化疗(HIPEC)的临床效果。方法选择2017年8月至2019年8月唐山弘慈医院肿瘤综合治疗科收治的结直肠癌合并恶性腹水患者95例,分为A、B两组,A组35例行贝伐珠单抗联合腹腔热灌注化疗(Bevacizumab+HIPEC),B组60例行常规腹腔内注射化疗,两组患者均联合卡培他滨口服化疗。行2个周期治疗后,比较两组患者血清肿瘤标志物CEA、CA199水平,缓解率(ORR)、控制率(DCR)、生活质量(QOL)、治疗毒性反应。结果A组比B组血清CEA、CA199水平降低(P<0.01),ORR、DCR、QOL均提高(P<0.05),差异均有统计学意义。两组治疗毒性反应比较差异无统计学意义。结论结直肠癌并发恶性腹水患者行Bevacizumab+HIPEC可行、有效。Objective To evaluate clinical effects of bevacizumab combined with hyperthermic intraperitoneal chemotherapy(HIPEC)in patients with colorectal cancer complicated with malignant ascites.Methods Totally 95 colorectal cancer patients with malignant ascites,who underwent treatment in the Department of Comprehensive Cancer Therapy,Tangshan Hongci Hospital from August 2017 to August 2019,were divided into group A(n=35)and group B(n=60).Group A received bevacizumab combined with hyperthermic intraperitoneal chemotherapy,group B received routine intraperitoneal chemotherapy,and both groups received oral chemotherapy with capecitabine.After two cycles of treatment,CEA,CA199,objective response rate(ORR),disease control rate(DCR),quality of life(QOL)and toxic reaction were compared between the two groups.Results Compared with group B,the level of CEA and CA199 of group A was lower(P<0.01),while ORR,DCR and improvement of QOL of group A was higher(P<0.05).The difference in treatment-related toxic reactions did not show significance.Conclusion Bevacizumab combined with hyperthermic intraperitoneal chemotherapy is a feasible and effective approach to colorectal cancer patients with malignant ascites.

关 键 词：结直肠癌 恶性腹水 贝伐珠单抗 腹腔热灌注化疗 

分 类 号：R735.34[医药卫生—肿瘤]